What does Alector, Inc. do?
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta…
What is Alector, Inc.'s P/E and P/B ratio?
Alector, Inc. has a P/E ratio of -1.7 and a P/B ratio of -20.49.
What is Alector, Inc.'s debt-to-equity ratio?
Alector, Inc. has a debt-to-equity ratio of 1.18.
How much does Alector, Inc. owe compared with what it owns?
Alector, Inc. owes $1.05 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Alector, Inc.'s Positivity rank?
Alector, Inc. is ranked #6,615 of 6,774 companies globally and #3,855 of 4,000 in United States on PositoAI, with a Positivity Score of -30,451.
Does Alector, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Alector, Inc..
Where can I read the latest news about Alector, Inc.?
Recent headlines about Alector, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Alector, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Alector, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.